Drug intelligence / Profile preview

Pregaloy NT

Development stage
Unknown
Lead developer
Lloyd Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

Pregaloy NT is a fixed-dose combination tablet developed and marketed by Lloyd Healthcare, containing 75 mg of pregabalin and 10 mg of nortriptyline. It is primarily indicated for the management of various neuropathic pain conditions, including diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. Pregabalin, an anticonvulsant, acts as an alpha-2 delta ligand that binds to the alpha-2 delta subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters such as glutamate and substance P. Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, enhancing the descending inhibitory pain pathways in the brain and spinal cord. Together, these components provide a synergistic effect in modulating pain signals traveling through damaged nerves.

Brand names
Pregaloy NT
Other names
Pregabalin + Nortriptyline
02

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on Pregaloy NT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pregaloy NT.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call